REFRACTORY RENAL CELL CARCINOMA
Clinical trials for REFRACTORY RENAL CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY RENAL CELL CARCINOMA trials appear
Sign up with your email to follow new studies for REFRACTORY RENAL CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill shows promise for Hard-to-Treat kidney cancer
Disease control TerminatedThis study tested an oral drug called NKT2152 in people with advanced clear cell renal cell carcinoma that had worsened after other treatments. The goal was to find the safest dose and see if it could shrink tumors. The trial was terminated early, but the data may still help guid…
Matched conditions: REFRACTORY RENAL CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Kidney cancer combo trial halted early – what we know
Disease control TerminatedThis study tested a new drug (NKT2152) combined with two other medicines (palbociclib and sasanlimab) in people with advanced clear cell kidney cancer that had worsened after prior treatments. The goal was to see if the combination was safe and could shrink tumors. The trial was …
Matched conditions: REFRACTORY RENAL CELL CARCINOMA
Phase: PHASE2 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC